A Phase I Dose-finding and Pharmacokinetic Study of Intravenous RTA 744 Injection in Patients With Recurrent or Refractory Anaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO), Anaplastic Mixed Oligo-astrocytoma (AOA), Glioblastoma Multiforme (GBM) or Gliosarcoma (GS), With or Without Concurrent Treatment With Enzyme-inducing Anticonvulsant Therapy

Trial Profile

A Phase I Dose-finding and Pharmacokinetic Study of Intravenous RTA 744 Injection in Patients With Recurrent or Refractory Anaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO), Anaplastic Mixed Oligo-astrocytoma (AOA), Glioblastoma Multiforme (GBM) or Gliosarcoma (GS), With or Without Concurrent Treatment With Enzyme-inducing Anticonvulsant Therapy

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2014

At a glance

  • Drugs Berubicin (Primary)
  • Indications Anaplastic astrocytoma; Glioma; Gliosarcoma
  • Focus Adverse reactions
  • Sponsors Reata Pharmaceuticals
  • Most Recent Events

    • 19 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Nov 2008 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top